Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Search Results to Dara L. Aisner

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Aisner, Dara

Item TypeName
Academic Article Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Academic Article Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Academic Article Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
Concept Protein Kinase Inhibitors
Academic Article Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
Academic Article Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
Academic Article Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
Academic Article Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.
Academic Article EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.
Academic Article BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
Academic Article Activation of RAS family members confers resistance to ROS1 targeting drugs.
Academic Article Rociletinib in EGFR-mutated non-small-cell lung cancer.
Academic Article An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Academic Article An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
Academic Article Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung.
Academic Article Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Academic Article Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Academic Article Updated Molecular Testing Guideline for the?Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the?International Association for the Study of Lung Cancer, and the?Association for Molecular Pathology.
Academic Article Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.
Academic Article Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
Academic Article A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
Academic Article Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Academic Article Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy.
Academic Article Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer.
Academic Article CSF Cytology Identifies Mechanisms of Tyrosine Kinase Inhibitor Resistance in Patient With EGFR-Mutated NSCLC With CNS Progression.

Search Criteria
  • Protein Kinase Inhibitors

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)